Boehringer Ingelheim Strengthens Antibody-Drug Conjugate Portfolio With New NBE ...
CHF 27 million investment significantly bolsters Boehringer's ADC portfolio, driven by its subsidiary, NBE Therapeutics, to achieve the c ...